Advancing Access to Better Diagnostics for Febrile Childhood Illnesses
Despite enormous progress in reducing child death in low and middle-income countries, still too many children die due to wrong diagnosis and treatment. A high proportion receives antibiotics although they do not suffer from bacterial infections. The proposed initiative strives to accelerate the uptake of innovative, affordable and easy-to-use diagnostics that help health workers differentiate between different causes of fever and give appropriate treatment. This will contribute to reduced use of antibiotics, better health and less antimicrobial resistance.
- Autre organisation suisse non-profit
- Product Development Partnerships (PDPs) supported by SDC in the area of malaria and neglected tropical diseases
- R4D research project on the etiology of fever, supported by SDC
- Bilateral malaria programs supported by SDC
- Global Antibiotic Research and Development Partnership supported by the Federal Office of Public Health
- Global health actors (inter alia WHO including TDR, GFATM, Unitaid) that are key drivers in the endeavor to improve access to quality affordable medical products
|Contexte||Currently over 75% of children seeking care at health facilities in low- and middle income contries present fever symptoms. Nowadays, most of them receive antibiotics unless they are identified to have malaria. Yet, many of these children do not need antibiotics because they suffer from viral illnesses that cannot be addressed with antibiotics. Improved access to and appropriate use of better rapid diagnostic tests to differentiate viral from bacterial infections for the management of febrile childhood illness is thus urgently needed. Improved access to better diagnostics will not only improve service delivery and health outcomes, but also limit the global threat of antimicrobial resistance.|
|Objectifs||Equitable access to (and appropriate use of) innovative, affordable and easy-to-use diagnostics for improved management of febrile childhood illness|
The main direct beneficiaries of the project are children under five years of age in low- and middle income countries among who still die too often due to wrong diagnosis and treatment of febrile illness. Hence they will benefit from improved diagnosis for better health outcomes.
The second category of beneficiaries are health professionals who will deliver better quality services and gain recognition from the communities.
The third category will be health authorities who will limit the prescription of antibiotics and hence reduce service costs, which will ultimately benefit the global population in view of the growing threat of antimicrobial resistance.
|Effets à moyen terme||The main outcome of this time-limited support is a platform that accelerates the uptake and appropriate use of innovative, affordable and easy-to-use diagnostics for febrile childhood illness.|
Principaux résultats attendus:
The key outputs of the single phase are:
Output 1: Real-world evidence base and publications from 5 country demonstration projects to inform policy decisions and behavior change for new diagnostic solutions that enable appropriate fever management and antibiotic prescription
Output 2: Proven electronic decision-aid tools that can be used hand-in-hand with diagnostics and empower providers to optimize diagnostic and care pathways
Output 3: Advanced market understanding (regulatory, policy, user readiness and cost-effectiveness) for uptake of new tools
Output 4: Stimulate and attract funding for future expansion of the Diagnostic Use Accelerator, including co-funding from low- and middle income countries.
|Direction/office fédéral responsable||
Coopération au développement
|Partenaire de projet||
Organisation suisse à but non lucratif
Foundation for Innovative New Diagnostics (FIND)
|Coordination avec d'autres projets et acteurs||
|Budget||Phase en cours Budget de la Suisse CHF 1'500'000 Budget suisse déjà attribué CHF 894'700|